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1 |  INTRODUCTION
Heterozygous germline mutations in MMR genes cause 
Lynch syndrome (LS), an autosomal dominant condition 
which predisposes to various types of cancer including 
colorectal cancer (CRC) and endometrial cancer (Hampel 
et al., 2008, 2006). In contrast to other hereditary CRC 
syndromes, for example Familial Adenomatous Polyposis, 
de novo germline mutations in MMR genes are described 
(Plasilova et al., 2006; Stulp et al., 2006) but appear to 
be rare. Only 2.3% of MMR gene mutation carriers are 
reported to have a de novo mutation (Win et al., 2011). 
Biallelic somatic MMR gene aberrations have been de-
scribed more frequently, and account for 50%–70% of mi-
crosatellite instable (MSI) tumors without causal germline 
mutations or promotor methylation (Geurts‐Giele et al., 
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Abstract
Background: Lynch syndrome (LS) is caused by germline mismatch repair (MMR) 
gene mutations. De novo MMR gene mutations are rare, and somatic mosaicism in 
LS is thought to be infrequent. We describe the first case of somatic mosaicism by a 
de novo MLH1 mutation for a patient diagnosed with a rectosigmoid adenocarci-
noma at age 31.
Methods: Twelve years after initial colorectal cancer diagnosis, tumor tissue of the 
patient was tested with sensitive next generation sequencing (NGS) analysis for the 
presence of somatic MMR mutations.
Results: In tumor tissue, an inactivating MLH1 mutation (c.518_519del; 
p.(Tyr173Trpfs*18)) was detected, which was also present at low level in the blood 
of the patient. In both parents, as well as the patient's sisters, the mutation was not 
present.
Conclusion: We show that low‐level mosaicism can be detected by using high‐cov-
erage targeted NGS panels on constitutional and/or tumor DNA. This report illus-
trates that by using sensitive sequencing techniques, more cases of genetic diseases 
driven by mosaic mutations may be identified, with important clinical consequences 
for patients and family members.
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2014; Haraldsdottir et al., 2014; Mensenkamp et al., 2014). 
Somatic mosaicism is the presence of two or more popula-
tions of cells with different genotypes in one individual, and 
can cause the development of neoplasia if involving a gene 
related with oncogenesis (Hall, 1988). Somatic mosaicism 
in LS is thought to be very infrequent; to our knowledge, 
only two cases have been described thus far. Pastrello et al. 
(2009) describe somatic mosaicism in a LS patient caused 
by reversion of an inherited mutation in MLH1 (OMIM 
120436), this mutation was present in >80% of both blood 
and tissues. Furthermore, Sourrouille et al. (2013) describe 
a patient with somatic mosaicism due to a de novo mutation 
in MSH2 (OMIM 609309), which was detected in normal 
colonic tissue but not in the blood. This mosaic MSH2 mu-
tation apparently had germline transmission since this mu-
tation was also present in the patient's son. Here, we report 
the first case of somatic mosaicism by a de novo MLH1 
mutation.
Our male index patient was diagnosed with a rectosig-
moid adenocarcinoma at the age of 31. The patient had no 
relevant medical history. He has two healthy sisters and no 
offspring. Both his father and mother did not develop any 
tumor during life and died at 85 and 80 years of age, respec-
tively. A brother of his mother had bladder cancer at age 67, 
and grandfather from mother's side died from liver cancer di-
agnosed at age 66.
Because of his young age, he was referred for ge-
netic counseling to the Familial Cancer Clinic. 
Immunohistochemistry (IHC) of the MMR proteins was 
performed on the tumor tissue, which showed normal nu-
clear expression of MSH2 and MSH6 but absence of nu-
clear expression of MLH1 and PMS2. Molecular analyses 
showed MSI without MLH1 promotor methylation in the 
tumor tissue. Mutation scanning of the four MMR genes by 
denaturing gradient gel electrophoresis (DGGE) of DNA 
isolated from blood showed no indication for the presence 
of a germline mutation. The bladder tumor of the index pa-
tient's uncle was also examined but did not show any signs 
of MSI (IHC was not possible). Based on these results, the 
patient was considered to be Lynch‐like. Therefore he and 
his sisters underwent colonoscopy every 2 years, no polyps 
were identified. Additionally, surveillance for extra‐colonic 
tumors was advised to him and his sisters. One sister de-
cided to have her ovaries and uterus preventively removed 
at 46 years of age. In both organs, no signs of neoplastic 
growth were observed.
Recently, all Lynch‐like patients of the Familial Cancer 
Clinic at the Netherlands Cancer Institute are being evalu-
ated for somatic MMR gene mutations, as the presence of a 
somatic MMR gene mutation can indicate a sporadic origin 
of the tumor. Therefore, last year the index patient visited 
the Familial Cancer Clinic again, 12 years after the initial 
CRC diagnosis. Subsequently, the tumor was tested with next 
generation sequencing (NGS) for the presence of somatic 
MMR mutations.
2 |  MATERIALS AND METHODS
2.1 | Ethical compliance
The index patient was counseled by the Familial Cancer 
Clinic and provided informed consent.
2.2 | Somatic mutation analysis of the 
MMR genes
Normal and tumor tissues of the index patient were manu-
ally microdissected from five to ten hematoxylin‐stained 
sections of formalin‐fixed paraffin‐embedded (FFPE) tis-
sue, after which proteinase K and 5% Chelex 100 resin was 
added for DNA isolation, as previously described (van Lier 
et al., 2010). DNA concentrations were measured with the 
Qubit 2.0 Fluorometer and 10 ng DNA input was used for 
mutation analysis. Mutation analysis with the Ion S5 XL sys-
tem (Ion Torrent) was performed with suppliers' materials 
and protocols (Thermo Fisher Scientific). A custom‐made 
primer panel was designed using the ampliseq designer. 
This panel targets the open reading frame including the 
intron–exon boundaries of MLH1 (NM_000249.3), MSH2 
(NM_000251.2), MSH6 (OMIM 600678, NM_000179.2), 
and PMS2 (OMIM 600259, NM_000535.7), with a coding 
sequence coverage of 97%, 94%, 95%, and 81% respectively, 
and hotspots for BRAF (OMIM 164757, NM_004333.5; 
exon 11 and 15), POLD1 (OMIM 174761, NM_002691.3; 
exon 12), and POLE (OMIM 174762, NM_006231.3; exon 
3 and 13). Furthermore, single nucleotide polymorphisms 
in and around the MLH1, MSH2, MSH6, and PMS2 genes 
are included to detect copy number variations, as previ-
ously described (Dubbink et al., 2016). Primer sequences 
are available on request.
Libraries were made using the Ion AmpliSeq Library 
Kit 2.0‐384 LV according to the Ion Ampliseq Library 
Preparation User Guide. Template was performed with 
the Ion 510/520/530 Chef kit and sequencing was per-
formed on a 530 chip using the Ion S5 XL system. Data 
were analyzed using SeqPilot version 4.2.2 (JSI medical 
systems).
2.3 | Sanger sequencing of MLH1
DNA isolation from blood of the index patient and his two 
sisters was performed using DNAzol (Thermo Fischer 
Scientific). DNA from normal FFPE tissue of the deceased 
parents was isolated using QIA Amp DNA purification kit 
(Qiagen). Sanger sequencing for MLH1 exon 6 was per-
formed using standard procedures.
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3 |  RESULTS
In the tumor, an inactivating MLH1 mutation (c.518_519del; 
p.(Tyr173Trpfs*18); see Figure 1) was identified and loss 
of the wild‐type MLH1 allele was seen, indicating biallelic 
MLH1 inactivation. This explains the MSI phenotype and the 
absence of nuclear expression of MLH1 and PMS2 in the 
tumor cells. Additionally, five missense variants of unknown 
significance were detected in tumor tissue only, one in MSH2 
(c.2198C>A; p.(Ala733Asp)) and four in MSH6 (c.821G>A; 
p.(Ser274Asn), c.1730G>A; p.(Arg577His), c.2419G>A; 
p.(Glu807Lys) and c.3163G>A; p.(Ala1055Thr)).
Surprisingly, the MLH1 mutation was also detected by 
NGS at low frequencies in DNA isolated from several normal 
tissues, including smooth muscle near the tumor, epithelium 
from the small intestine and lymph nodes without metastasis 
(see Table 1). NGS showed the presence of the inactivating 
MLH1 mutation with a variant allele frequency of 13% in the 
blood sample, a level that would not generally be detectable 
by DGGE. These results suggested mosaicism of the MLH1 
mutation in at least two germ layers. To rule out reversion of 
an inherited MLH1 mutation as described before (Pastrello et 
F I G U R E  1  MLH1ª c.518_519del; p.(Tyr173Trpfs*18) analysis. (a) NGS analysis of the colon adenocarcinoma showing the mutation in 80% 
of the reads. (b) NGS analysis of DNA isolated from blood showing the mutation in 13% of the reads. (c) Sanger sequencing of DNA isolated from 
blood confirming the presence of the MLH1 mutation (arrow indicates start of the deletion). ªOMIM 120436, NM_000249.3. NGS, next generation 
sequencing
T A B L E  1  Different tissues from the rectosigmoid resection of 
the index patient (including part of the bladder and ileum), as well as 
DNA isolated from blood, were included for somatic MMR gene 
sequencing analysis
Tissue
Neoplastic cell 
content as 
estimated by a 
GE pathologist
Variant allele 
frequency (VAF) of 
MLH1a c.518_519del; 
p.(Tyr173Trpfs*18)
Colon 
adenocarcinoma
70% 80%b 
Colon muscle near 
adenocarcinoma
0% 14%
Small intestine 
muscle
0% 16%
Small intestine 
epithelium
0% 14%
Lymph node 0% 14%
Blood sample (in 
duplo)
Not applicable 13%
Abbreviation: MMR, mismatch repair.
aOMIM 120436, NM_000249.3. bVAF indicative for loss of the wild‐type allele. 
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al., 2009), normal tissue of the deceased parents was tested 
using Sanger sequencing for the presence of the MLH1 muta-
tion. In both parents, the mutation was not detected, indicat-
ing the appearance of a post‐zygotic de novo mutation in the 
index patient. As expected, the mutation was also not iden-
tified in the DNA isolated from blood of the patient's two 
sisters. Therefore his sisters were dismissed from further LS 
surveillance.
It is thought that somatic mosaicism gives a milder phe-
notype than full LS depending on the extend of the mosa-
icism in the cell types prone for malignant transformation 
(Hall, 1988). However, as the degree of mosaicism can 
vary strongly, even within an organ or cell type (Forsberg, 
Gisselsson, & Dumanski, 2017), it is impossible to estimate 
the patients' risk for various types of cancer based on the mu-
tation rate. Therefore, the index patient is now considered to 
be a LS patient and is advised the regular LS surveillance. As 
the patient does not have offspring, we cannot check for go-
nadal mosaicism. After the above results were obtained, the 
patient continued the LS surveillance program.
4 |  DISCUSSION
As described previously for other mosaic cases, this report 
highlights that, as former gene scanning techniques in clini-
cal genetics laboratories will be replaced by deep sequenc-
ing techniques, more cases of genetic diseases driven by 
mosaic mutations may be identified, with important clinical 
consequences for patients and family members. If no patho-
genic mutation is detected in the blood, mutational analysis 
of tumor tissue might help to identify low‐level mosaicism. 
All neoplastic cells will most likely harbor the pathogenic 
mutation, and loss of the wild‐type allele, a common event 
for tumor suppressor genes, enriches for the pathogenic mu-
tation even further. If a mutation is detected in tumor tissue, 
the surrounding normal tissue and constitutional DNA can 
be screened for the presence of this specific mutation with 
very sensitive techniques (like NGS), enabling detection of 
low‐frequency mutations.
When routine mutation analysis of constitutional DNA 
from patients with a clear clinical suspicion for a tumor 
syndrome is negative, one should consider to perform high‐
coverage targeted NGS of the indicated genes to detect pos-
sible mosaicism. Furthermore, sequencing of tumor tissue 
can guide detection of a low‐level mosaic variant in the 
germline. This diagnostic strategy will result in improved 
health care both for the index patient and his or her family 
members.
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